Jupiter Neurosciences, Inc. announced the completion of its Phase I clinical trial with its proprietary JOTROL™, an enhanced formulation of resveratrol with increased bioavailability. Jupiter is a clinical-stage drug platform company focused on making a significant impact for patients and society through a safe and oral medication intended to treat Alzheimer's disease and a broad spectrum of rare diseases. In this first-in-man trial, JOTROL™ was administered in ascending doses in normal healthy volunteers to assess safety, tolerability, and pharmacokinetics.

JOTROL™ was determined to be safe and well tolerated at all dose levels administered, with the data safety monitoring board (DSMB) reporting no serious adverse events (SAEs). Additionally, JOTROLTM demonstrated blood plasma levels 8-10-fold higher than naïve resveratrol administered in historical clinical trials, meeting performance objectives. The study was financed by a grant from the National Institute on Aging (NIA), entitled Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease.